



Section 708AA Notice

For Immediate Release:

May 3, 2017

Market Announcements Office
ASX Limited
20 Bridge Street
Sydney NSW 2000

Simavita Limited (**Simavita** or **the Company**) gives notice in accordance with Section 708AA (2)(f) of the Corporations Act, 2001 (**the Act**) that:

1. The Company will offer to issue without disclosure to investors under Part 6D.2 of the Act, 35,885,265 CHESS Depository Interests (**CDIs**) at an issue price of 4 cents per CDI under a non-renounceable rights issue on the basis of 1 CDI for every 7 CDIs held at 7:00pm (AEST) on 8 May 2017 (**Record Date**) by CDI Holders whose address on the Company's register of members is in Australia and New Zealand.
2. This notice is being given under section 708AA(2)(f) of the Act.
3. As at the date of this announcement, Simavita has complied with:
 - (a) section 601CK of the Act; and
 - (b) section 674 of the Act.
4. As at the date of this announcement, there is no information:
 - (a) that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules; and
 - (b) that investors and their professional advisers would reasonably require, and would reasonably expect to find in a disclosure document, for the purpose of making an informed assessment of:
 - (i) the assets and liabilities, financial position and performance, profits and losses and prospects of Simavita; or
 - (ii) the rights and liabilities attaching to the CDIs.
5. The Rights Issue will not have any material effect on the control of Simavita. The capital structure before the Rights Issue and the potential structure after the Rights Issue is set out below:

Issued CDIs	Number of CDIs
Total issued capital of Simavita at the Record Date for the Rights Issue	251,196,860
Number of CDIs offered under the Rights Issue including any shortfall CDIs and subject to rounding	35,885,265
Issue of placement CDIs	37,500,000

Total issued capital of Simavita at completion of Rights Issue assuming maximum number of CDIs under the Rights Issue are issued	324,582,125
--	-------------

The Directors have reserved the right to offer any shortfall under the Rights Issue in accordance with Listing Rule 7.2 Exception 3.

Investors should note the following:

- (a) If particular eligible CDI holders do not take up all of their entitlements under the offer, the CDI interests of those eligible CDI holders will be diluted;
- (b) The proportional interests of CDI holders with registered addresses outside Australia and New Zealand will be diluted because those CDI holders are not entitled to participate in the Rights Issue; and
- (c) Should Simavita's major CDI holders subscribe for their full entitlement under the Rights Issue, there will not be any material impact on the control of the Company following the issue of CDIs under the Rights Issue.

Further details about the Rights Issue were announced on 3 May 2017.

For further information, please view our website (www.simavita.com) or contact:

Ms Peta Jurd
Chief Commercial Officer

E: pjurd@simavita.com
T: +61 421 466 653
W: Investor Centre: [Click here](#)

About Simavita

Simavita (ASX: SVA) develops and markets advanced systems associated with smart, wearable and disposable sensors for the health care industry. Our first products focus on major unmet needs for the assessment and management of incontinence. The annual global economic burden is billions of dollars for incontinence diapers alone and is increasing rapidly.

Simavita operates in Australia, Europe and North America where there is a significant and growing demand for products that deliver real clinical and cost benefits to the health care industry.

With the support of our shareholders, customers and employees, Simavita is absolutely committed to the business at hand; creating a commercially successful and growing corporation. www.simavita.com